Truist Securities analyst Danielle Brill raised the price target on Biogen (NASDAQ: BIIB) to $190.00 (from $189.00) while maintaining a Hold rating.

The analyst comments "We updated our model following BIIB’s 1Q results (see our prior quick take). Minor adjustments to our forecasts, reflecting mgmt commentary on the 2026 outlook, result in a slightly higher PT of $190 (from $189). While 1Q26 revenue were modestly above our prior estimates, our broader concerns regarding the company’s forward revenue growth trajectory remain unchanged. As such, we reiterate our HOLD rating."